03.11.2009 21:05:00
|
Dolby Laboratories Reports FY 2009 Fourth Quarter and Year-End Financial Results
Dolby Laboratories, Inc. (NYSE:DLB) today announced the Company's financial results for the fourth quarter and fiscal year ended September 25, 2009.
For the fourth quarter, Dolby reported total revenue of $163.9 million, compared to $163.1 million for the fourth quarter of fiscal 2008.
Fourth quarter net income was $44.3 million, or $0.38 per diluted share, compared to $48.6 million, or $0.42 per diluted share, for the fourth quarter of fiscal 2008.
For fiscal year 2009, Dolby reported total revenue of $719.5 million, compared to $640.2 million for fiscal year 2008, an increase of 12 percent. Net income for fiscal year 2009 was $243.0 million, or $2.11 per diluted share, compared to $199.5 million, or $1.74 per diluted share, for fiscal year 2008.
Reflected in Dolby’s fiscal 2009 earnings was a $20.0 million gain in the first quarter resulting from an amendment to a license agreement with an unrelated patent licensor, and $4.8 million in restructuring charges primarily related to the consolidation of our manufacturing operations.
"We had a solid fourth quarter and fiscal year,” said Kevin Yeaman, President and Chief Executive Officer, Dolby Laboratories. "In fiscal 2009, we made excellent progress with new wins in many of our markets, including broadcast, mobile, and personal computer, and we remain focused on growing the adoption of our surround sound solutions globally while bringing new technologies to market.”
Guidance
For fiscal 2010, Dolby is targeting revenue of $720 million to $750 million, total gross margin of approximately 88 percent on a GAAP basis, and 89 percent on a non-GAAP basis. In addition, Dolby is targeting fiscal 2010 operating expenses of $313 million to $324 million on a GAAP basis and $280 million to $290 million on a non-GAAP basis, and a tax rate of approximately 35 percent on a GAAP basis and non-GAAP basis. Dolby’s non-GAAP measures exclude expenses related to stock-based compensation, the amortization of intangibles from business combinations, and restructuring charges.
These targets lead to a fiscal 2010 diluted earnings per share target range of $1.85 to $1.96 on a GAAP basis and $2.07 to $2.20 on a non-GAAP basis.
A reconciliation between GAAP and non-GAAP financial targets is provided at the end of this press release.
The Company's Conference Call Information
Members of Dolby management will lead a conference call open to all interested parties to discuss Dolby Laboratories’ Q4 and year-end fiscal 2009 financial results at 2:00 p.m. PT/5:00 p.m. ET on Tuesday, November 3, 2009.
Access to the teleconference will be available over the Internet at http://investor.dolby.com/medialist.cfm or by dialing 888-797-3001. International callers can access the conference call at 913-312-0684.
A replay of the call will be available beginning at 5:00 p.m. PT on Tuesday, November 3, 2009, until 9:00 p.m. PT on November 10, 2009 at 888-203-1112 (international callers can access the replay at 719-457-0820) and entering the confirmation code 4818739. An archived version of the teleconference will also be available on www.dolby.com.
Non-GAAP Financial Information
To supplement Dolby’s financial statements presented on a GAAP basis, Dolby provides non-GAAP financial measures of gross margin, operating expense, tax rate, and diluted earnings per share. These measures are adjusted to exclude the charges and expenses discussed above. Dolby presents such non-GAAP financial measures in reporting its financial results to provide investors with an additional tool to evaluate Dolby’s operating results in a manner that focuses on what Dolby’s management believes to be its ongoing business operations. Dolby’s management believes it is useful for itself and investors to review, as applicable, both GAAP information that includes the impact of stock-based compensation expense, amortization of acquired intangible assets through business combinations, restructuring charges, and the related tax impact of all of these items on the provision for income taxes, and the non-GAAP measures that exclude such information in order to assess the performance of Dolby’s business for planning and forecasting in subsequent periods. Dolby’s management does not itself, nor does it suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Whenever Dolby uses such a non-GAAP financial measure, it provides a reconciliation of the non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed above. Investors are also encouraged to review Dolby’s GAAP financial statements as reported in its SEC filings.
Forward-Looking Statements
Certain statements in this press release, including statements relating to Dolby's expectations regarding revenue, gross margin, operating expense, tax rate, and diluted earnings per share for fiscal 2010, the progress Dolby is making in its markets, the further adoption of Dolby surround sound solutions and other technologies, and the benefits that may be derived therefrom are "forward-looking statements” that are subject to risks and uncertainties. These forward-looking statements are based on management’s current expectations, and as a result of certain risks and uncertainties actual results may differ materially from those projected. The following important factors, without limitation, could cause actual results to differ materially from those in the forward-looking statements: risks associated with the effects of the economic recession both domestically and internationally; risks associated with trends in the markets in which Dolby operates, including the DVD and Blu-ray Disc™, broadcast, personal computer, consumer electronics, gaming, mobile, and automobile markets; pricing pressures; the timing of Dolby's receipt of royalty reports and/or payments from its licensees; Dolby’s accuracy of calculation of royalties due to its licensors; Dolby’s ability to develop, maintain, and strengthen relationships with industry participants; Dolby’s ability to develop and deliver innovative technologies in response to new and growing markets in the entertainment industry; competitive risks; risks associated with conducting business in China and other countries that have historically limited recognition and enforcement of intellectual property and contractual rights; risks associated with the health of the motion picture industry generally; the development and growth of the market for digital cinema and digital 3D and Dolby’s ability to successfully penetrate this market; Dolby’s ability to expand its business generally, and to expand its business beyond sound technologies to other technologies related to digital entertainment delivery, by acquiring and successfully integrating businesses or technologies; and other risks detailed in Dolby’s Securities and Exchange Commission filings and reports, including the risks identified under the section captioned "Risk Factors” in its most recent Quarterly Report on Form 10-Q. Dolby disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
About Dolby Laboratories
Dolby Laboratories (NYSE:DLB) is the global leader in technologies that are essential elements in the best entertainment experiences. Founded in 1965 and best known for high-quality audio and surround sound, Dolby creates innovations that enrich entertainment at the movies, at home, or on the go. Visit www.dolby.com for more information.
Dolby and the double-D symbol are registered trademarks of Dolby Laboratories. Blu-ray Disc is a trademark of Blu-ray Disc Association. S09/22074 DLB-F
DOLBY LABORATORIES, INC. | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
Fiscal Quarter Ended | Fiscal Year-to-Date Ended | |||||||||||||||
September 26, |
September 25, |
September 26, |
September 25, |
|||||||||||||
(unaudited) | ||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||
Revenue: | ||||||||||||||||
Licensing | $ | 137,756 | $ | 138,621 | $ | 537,363 | $ | 594,697 | ||||||||
Product sales | 18,586 | 20,223 | 72,284 | 95,967 | ||||||||||||
Services | 6,788 | 5,033 | 30,584 | 28,839 | ||||||||||||
Total revenue | 163,130 | 163,877 | 640,231 | 719,503 | ||||||||||||
Cost of revenue: | ||||||||||||||||
Cost of licensing | 3,623 | 3,580 | 15,802 | 14,803 | ||||||||||||
Cost of product sales (1) |
9,806 | 10,444 | 39,455 | 57,220 | ||||||||||||
Cost of services (1) | 3,120 | 3,240 | 12,520 | 12,786 | ||||||||||||
Gain from amended patent licensing agreement | - | - | - | (20,041 | ) | |||||||||||
Total cost of revenue | 16,549 | 17,264 | 67,777 | 64,768 | ||||||||||||
Gross margin | 146,581 | 146,613 | 572,454 | 654,735 | ||||||||||||
Operating expenses: | ||||||||||||||||
Selling, general and administrative (1) | 62,815 | 62,514 | 224,090 | 225,489 | ||||||||||||
Research and development (1) | 17,082 | 18,079 | 62,080 | 66,710 | ||||||||||||
Restructuring charges, net | - | 835 | - | 4,847 | ||||||||||||
Gain on settlements | - | (77 | ) | (499 | ) | (5,977 | ) | |||||||||
Total operating expenses | 79,897 | 81,351 | 285,671 | 291,069 | ||||||||||||
Operating income | 66,684 | 65,262 | 286,783 | 363,666 | ||||||||||||
Other income, net | 4,750 | 1,959 | 15,019 | 7,753 | ||||||||||||
Income before provision for income taxes and controlling interest | 71,434 | 67,221 | 301,802 | 371,419 | ||||||||||||
Provision for income taxes | (22,254 | ) | (22,518 | ) | (100,770 | ) | (127,073 | ) | ||||||||
Income before controlling interest | 49,180 | 44,703 | 201,032 | 244,346 | ||||||||||||
Controlling interest in net income | (621 | ) | (404 | ) | (1,574 | ) | (1,355 | ) | ||||||||
Net income | $ | 48,559 | $ | 44,299 | $ | 199,458 | $ | 242,991 | ||||||||
Basic earnings per share | $ | 0.43 | $ | 0.39 | $ | 1.79 | $ | 2.15 | ||||||||
Diluted earnings per share | $ | 0.42 | $ | 0.38 | $ | 1.74 | $ | 2.11 | ||||||||
Weighted-average shares outstanding (basic) | 112,342 | 113,684 | 111,492 | 113,101 | ||||||||||||
Weighted-average shares outstanding (diluted) | 115,010 | 115,845 | 114,781 | 115,367 | ||||||||||||
(1) Stock-based compensation included above was classified as follows: | ||||||||||||||||
Cost of product sales | $ | 183 | $ | 93 | $ | 853 | $ | 564 | ||||||||
Cost of services | 51 | 30 | 177 | 115 | ||||||||||||
Selling, general and administrative | 4,110 | 5,076 | 17,267 | 17,309 | ||||||||||||
Research and development | 1,136 | 1,248 | 4,413 | 4,434 | ||||||||||||
DOLBY LABORATORIES, INC. | ||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
September 26, 2008 |
September 25, 2009 |
|||||
(unaudited) | ||||||
(in thousands) | ||||||
ASSETS | ||||||
Current assets: | ||||||
Cash and cash equivalents | $ | 394,761 | $ | 451,678 | ||
Short-term investments | 119,667 | 283,808 | ||||
Accounts receivable, net | 27,650 | 22,981 | ||||
Inventories | 18,133 | 12,975 | ||||
Deferred taxes | 91,824 | 83,438 | ||||
Prepaid expenses and other current assets | 39,834 | 45,958 | ||||
Total current assets | 691,869 | 900,838 | ||||
Property, plant and equipment, net | 87,915 | 92,178 | ||||
Intangible assets, net | 83,060 | 82,035 | ||||
Goodwill | 250,356 | 261,121 | ||||
Long-term investments | 180,996 | 205,938 | ||||
Deferred taxes | 24,900 | 23,755 | ||||
Other assets | 17,050 | 15,450 | ||||
Total assets | $ | 1,336,146 | $ | 1,581,315 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
Current liabilities: | ||||||
Accounts payable and accrued liabilities | $ | 156,925 | $ | 113,822 | ||
Income taxes payable | 4,811 | 3,934 | ||||
Current portion of long-term debt | 1,593 | 1,624 | ||||
Deferred revenue | 37,344 | 37,204 | ||||
Total current liabilities | 200,673 | 156,584 | ||||
Long-term debt | 7,782 | 5,825 | ||||
Deferred revenue | 6,171 | 10,759 | ||||
Deferred taxes | 16,755 | 13,573 | ||||
Other liabilities | 33,414 | 31,469 | ||||
Total liabilities | 264,795 | 218,210 | ||||
Controlling interest | 22,098 | 21,997 | ||||
Stockholders' equity: | ||||||
Class A common stock | 52 | 53 | ||||
Class B common stock | 60 | 60 | ||||
Additional paid-in capital | 434,907 | 478,979 | ||||
Retained earnings | 609,495 | 852,475 | ||||
Accumulated other comprehensive income | 4,739 | 9,541 | ||||
Total stockholders' equity | 1,049,253 | 1,341,108 | ||||
Total liabilities and stockholders' equity | $ | 1,336,146 | $ | 1,581,315 | ||
DOLBY LABORATORIES, INC. | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||||||
Fiscal Quarter Ended | Fiscal Year-to-Date Ended | |||||||||||||||
September 26, |
September 25, |
September 26, |
September 25, |
|||||||||||||
(unaudited) | ||||||||||||||||
(in thousands) | ||||||||||||||||
Operating activities: | ||||||||||||||||
Net income | $ | 48,559 | $ | 44,299 | $ | 199,458 | $ | 242,991 | ||||||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||||
Depreciation and amortization | 5,407 | 7,231 | 24,814 | 28,732 | ||||||||||||
Stock-based compensation expense | 5,102 | 6,207 | 22,332 | 21,758 | ||||||||||||
Accretion of discounts/amortization of premium on investments | 2,037 | 1,647 | 1,904 | 5,589 | ||||||||||||
Excess tax benefit from exercise of stock options | (3,229 | ) | (2,279 | ) | (21,746 | ) | (5,827 | ) | ||||||||
Provision for doubtful accounts | 168 | 244 | 935 | 1,392 | ||||||||||||
Deferred taxes | (1,265 | ) | (14,595 | ) | (21,750 | ) | 5,237 | |||||||||
Gain on Put Rights | - | (56 | ) | - | (9,508 | ) | ||||||||||
Unrealized losses on auction rate certificates | - | 15 | - | 10,869 | ||||||||||||
Gain from amended patent licensing agreement | - | - | - | (20,041 | ) | |||||||||||
Other non-cash items affecting net income | (43 | ) | 761 | 2,273 | 3,506 | |||||||||||
Changes in operating assets and liabilities: | ||||||||||||||||
Accounts receivable | 17,268 | 26,491 | 987 | 1,797 | ||||||||||||
Inventories | 1,307 | (3,783 | ) | (7,567 | ) | (3,638 | ) | |||||||||
Prepaid expenses and other assets | (9,105 | ) | (3,310 | ) | (18,640 | ) | (147 | ) | ||||||||
Accounts payable and accrued liabilities | 14,297 | 2,882 | 33,874 | (21,362 | ) | |||||||||||
Income taxes, net | 23,678 | 8,354 | 29,825 | 8,602 | ||||||||||||
Deferred revenue | 7,679 | 2,700 | 25,962 | 7,488 | ||||||||||||
Other liabilities | (9,399 | ) | 1,153 | (5,187 | ) | (1,213 | ) | |||||||||
Payment on litigation settlement | - | - | (3,000 | ) | (3,000 | ) | ||||||||||
Net cash provided by operating activities | 102,461 | 77,961 | 264,474 | 273,225 | ||||||||||||
Investing activities: | ||||||||||||||||
Purchases of available-for-sale securities | (91,069 | ) | (68,500 | ) | (304,097 | ) | (373,223 | ) | ||||||||
Proceeds from sale of available-for-sale and trading securities | 16,244 | 78,923 | 299,376 | 176,908 | ||||||||||||
Purchases of property, plant and equipment | (5,944 | ) | (4,758 | ) | (13,610 | ) | (13,994 | ) | ||||||||
Purchases of intangible assets | - | (1,250 | ) | - | (9,571 | ) | ||||||||||
Acquisitions, net of cash acquired | 129 | - | (253,047 | ) | (16,621 | ) | ||||||||||
Other | - | - | 40 | - | ||||||||||||
Net cash (used in) provided by investing activities |
(80,640 | ) | 4,415 | (271,338 | ) | (236,501 | ) | |||||||||
Financing activities: | ||||||||||||||||
Payments on debt | (390 | ) | (401 | ) | (1,536 | ) | (1,522 | ) | ||||||||
Proceeds from exercise of stock options | 2,637 | 4,306 | 13,553 | 13,716 | ||||||||||||
Issuance of Class A common stock (ESPP) |
- | 37 | 1,133 | 3,502 | ||||||||||||
Excess tax benefit from exercise of stock options | 3,229 | 2,279 | 21,746 | 5,827 | ||||||||||||
Net cash provided by financing activities | 5,476 | 6,221 | 34,896 | 21,523 | ||||||||||||
Effect of foreign exchange rate changes on cash and cash equivalents | (2,443 | ) | (295 | ) | (1,738 | ) | (1,330 | ) | ||||||||
Net increase in cash and cash equivalents | 24,854 | 88,302 | 26,294 | 56,917 | ||||||||||||
Cash and cash equivalents at beginning of period | 369,907 | 363,376 | 368,467 | 394,761 | ||||||||||||
Cash and cash equivalents at end of period | $ | 394,761 | $ | 451,678 | $ | 394,761 | $ | 451,678 | ||||||||
Fiscal Year 2010 Non-GAAP Financial Targets | |||
(In millions, except per share data) | |||
The following tables show the Company’s fiscal year 2010 non-GAAP financial targets reconciled to GAAP financial targets included in this release. |
|||
Gross margin: |
Fiscal Year |
||
GAAP gross margin | 88% | ||
Stock-based compensation | 0 | ||
Amortization of acquired intangibles | 1 | ||
Non-GAAP gross margin | 89% | ||
Operating expenses: |
Fiscal Year 2010 | ||
Low | High | ||
GAAP operating expenses | $313 | $324 | |
Stock-based compensation | (30) | (31) | |
Amortization of acquired intangibles | (3) | (3) | |
Non-GAAP operating expenses | $280 | $290 | |
Diluted earnings per share: |
Fiscal Year 2010 | ||
Low | High | ||
GAAP diluted earnings per share | $1.85 | $1.96 | |
Stock-based compensation | 0.26 | 0.27 | |
Amortization of acquired intangibles | 0.09 | 0.10 | |
Income tax adjustments | (0.13) | (0.13) | |
Non-GAAP diluted earnings per share | $2.07 | $2.20 | |
Shares used in computing diluted earnings per share | 116 | 115 |
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Dolby Laboratories Inc.mehr Nachrichten
18.11.24 |
Ausblick: Dolby Laboratories präsentiert Quartalsergebnisse (finanzen.net) | |
04.11.24 |
Erste Schätzungen: Dolby Laboratories stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
06.08.24 |
Ausblick: Dolby Laboratories verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) | |
23.07.24 |
Erste Schätzungen: Dolby Laboratories stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) |